Prevalence and correlates of prescription opioid use among US adults, 2019–2020

Zajacova, Anna; Grol-Prokopczyk, Hanna; Limani, Merita; Schwarz, Christopher G.; Gilron, Ian

doi:10.1371/journal.pone.0282536

Cited by 16 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In both the primary analysis and 2016–2020 model, living in the Midwest, South, or West relative to the Northeast increased the risk of both single- and multiwave opioid use. These findings are consistent with recent work documenting the same geographic variations in pain frequency, activity interference, and prescription opioid use ( Zajacova et al, 2022 , 2023 ). Schieber et al (2019) also support our findings by showing that doctors practicing in Western and (predominantly) Southern states were prescribing opioids for 30 or more days significantly more frequently than other U.S. regions.…”

Section: Discussionsupporting

confidence: 92%

Predictors of Multiwave Opioid Use Among Older American Adults

Fennell

Jacobson

Grol-Prokopczyk

2023

Innovation in Aging

Self Cite

View full text Add to dashboard Cite

Background and Objectives Despite limited analgesic benefits, long-term opioid therapy (L-TOT) is common among older adults with chronic pain. Extended opioid use poses a threat to older adults as aging metabolisms retain opioids for longer, increasing the risk of injury, overdose, and other negative health outcomes. In contrast to predictors of general opioid use, predictors of L-TOT in older adults are not well-documented. We aimed to identify such predictors using all available data on self-reported opioid use in the Health and Retirement Study. Research Design and Methods Using five waves of data, respondents (N=10,713) aged 51 and older were identified as reporting no opioid use (n= 8,621), a single wave of use (n=1,410), or multiple waves of use (n=682). We conducted a multinomial logistic regression to predict both single- and multi-wave opioid use relative to no use. Demographic, socioeconomic, geographic, health, and healthcare-related factors were included in our model. Results Multivariable findings show that, relative to non-users, both single- and multi-wave users were significantly more likely to be younger (RRR=1.33;RRR=2.88); report lower household wealth (RRR=1.47;RRR=2.88); live in the US Midwest (RRR=1.29;RRR=1.56), South (RRR=1.34;RRR=1.58), or West (RRR=1.46;RRR=2.34); experience interfering pain (RRR=1.59; RRR=3.39), back pain (RRR=1.35;RRR=1.53), or arthritic pain (RRR=1.46;RRR=2.32); and see the doctor frequently (RRR=1.50;RRR=2.02). Multi-wave users were less likely to be Black (RRR=0.69) or Hispanic (RRR=0.45), and less likely to be never married (RRR=0.52). Discussion and Implications We identified demographic, socioeconomic, geographic, and healthcare-related predictors of chronic multi-year opioid use. Our focus on individuals taking opioids for this extended duration is novel. Differences in opioid use by geographic region and frequency of doctor visits particularly warrant attention from policymakers and researchers. We make additional recommendations based on a sensitivity analysis limited to 2016-2020 data.

show abstract

Section: Discussionsupporting

confidence: 92%

Predictors of Multiwave Opioid Use Among Older American Adults

Fennell

Jacobson

Grol-Prokopczyk

2023

Innovation in Aging

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other drugs commonly used are psychoactive drugs (18% compared to 5.5% in general population) and cardiovascular drugs (17% compared to), which make sense since a high rate of coronary heart disease was described in the EUROMAC paper [ 4 ]. For comparison, 10.7% of U.S. adults used one or more prescribed pain medications in the past 30 days; 13% of males use over the counter analgesics weekly and 11.9% of US adults reported having used opioids in the past 12 months (data mainly from USA, 2015–2018) [ 32 – 34 ].…”

Section: Discussionmentioning

confidence: 99%

Data from the European registry for patients with McArdle disease (EUROMAC): functional status and social participation

Karazi,

Scalco,

Stemmerik

et al. 2023

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background The European registry for individuals with GSD5 and other muscle glycogenosis (EUROMAC) was launched to register rare muscle glycogenosis in Europe, to facilitate recruitment for research trials and to learn about the phenotypes and disseminate knowledge about the diseases. A network of twenty collaborating partners from eight European countries and the US contributed data on rare muscle glycogenosis in the EUROMAC registry. Methods Following the initial report on demographics, neuromuscular features and comorbidity (2020), we here present the data on social participation, previous and current treatments (medication, supplements, diet and rehabilitation) and limitations. Furthermore, the following questionnaires were used: Fatigue severity scale (FSS), WHO Disability Assessment Scale (DAS 2.0), health related quality of life (SF36) and International Physical Activity Questionnaire (IPAQ). Results Of 282 participants with confirmed diagnoses of muscle glycogenosis, 269 had GSD5. Of them 196 (73%) completed all questionnaires; for the others, the data were incomplete. The majority, 180 (67%) were currently working. Previous medical treatments included pain medication (23%) and rehabilitation treatment (60%). The carbohydrate-rich diet was reported to be beneficial for 68%, the low sucrose diet for 76% and the ketogenic diet for 88%. Almost all participants (93%) reported difficulties climbing stairs. The median FSS score was 5.22, indicating severe fatigue. The data from the WHODAS and IPAQ was not of sufficient quality to be interpreted. Conclusions The EUROMAC registry have provided insight into the functional and social status of participants with GSD5: most participants are socially active despite limitations in physical and daily life activities. Regular physical activity and different dietary approaches may alleviate fatigue and pain.

show abstract

“… 1 , 2 , 3 , 4 , 5 , 6 Opioid use is highly prevalent in the United States, and in 2020 an estimated 12% of adults in the United States had used prescription opioids within the past year. 7 Prolonged use of prescription opioids, such as oxycodone, has been linked to several adverse outcomes including a heightened risk of opioid use disorder (OUD) and opioid overdose. 8 , 9 Understanding the factors that contribute to inter‐individual variability in initial opioid experiences, such as prescription pain management, will help elucidate biological pathways implicated in problematic opioid use.…”

Section: Introductionmentioning

confidence: 99%

Genetic background and sex influence somatosensory sensitivity and oxycodone analgesia in the Hybrid Rat Diversity Panel

Duffy,

Ward,

Hale

et al. 2024

Genes Brain and Behavior

View full text Add to dashboard Cite

Opioid use disorder (OUD) is an ongoing public health concern in the United States, and relatively little work has addressed how genetic background contributes to OUD. Understanding the genetic contributions to oxycodone‐induced analgesia could provide insight into the early stages of OUD development. Here, we present findings from a behavioral phenotyping protocol using several inbred strains from the Hybrid Rat Diversity Panel. Our behavioral protocol included a modified “up‐down” von Frey procedure to measure inherent strain differences in the sensitivity to a mechanical stimulus on the hindpaw. We also performed the tail immersion assay, which measures the latency to display tail withdrawal in response to a hot water bath. Initial withdrawal thresholds were taken in drug‐naïve animals to record baseline thermal sensitivity across the strains. Oxycodone‐induced analgesia was measured after administration of oxycodone over the course of 2 h. Both mechanical and thermal sensitivity are shaped by genetic factors and display moderate heritability (h2 = 0.23–0.40). All strains displayed oxycodone‐induced analgesia that peaked at 15–30 min and returned to baseline by 2 h. There were significant differences between the strains in the magnitude and duration of their analgesic response to oxycodone, although the heritability estimates were quite modest (h2 = 0.10–0.15). These data demonstrate that genetic background confers differences in mechanical sensitivity, thermal sensitivity, and oxycodone‐induced analgesia.

show abstract

Prevalence and correlates of prescription opioid use among US adults, 2019–2020

Cited by 16 publications

References 47 publications

Predictors of Multiwave Opioid Use Among Older American Adults

Predictors of Multiwave Opioid Use Among Older American Adults

Data from the European registry for patients with McArdle disease (EUROMAC): functional status and social participation

Genetic background and sex influence somatosensory sensitivity and oxycodone analgesia in the Hybrid Rat Diversity Panel

Contact Info

Product

Resources

About